November 2015 - Cancer Currents Blog
- Lung Cancer Precision Medicine Trials: Adapting to Progress
Patients with lung cancer are benefiting from the boom in targeted and immune-based therapies. With a series of precision medicine trials, NCI is keeping pace with the rapidly changing treatment landscape for lung cancer.
- FDA Approves Talimogene Laherparepvec to Treat Metastatic Melanoma
The FDA has approved the first oncolytic virus therapy, talimogene laherparepvec (T-VEC). The drug was approved for the treatment of metastatic melanoma that cannot be removed surgically.
- FDA Approves Irinotecan Liposome to Treat Pancreatic Cancer
Patients with metastatic pancreatic cancer that has progressed after receiving gemcitabine-based chemotherapy now have a new treatment option: irinotecan liposome in combination with fluorouracil and leucovorin.
- How Genomics Is Shaping Precision Medicine in Oncology
In laboratories at NCI and around the world, researchers are using advanced genomic technologies to study the differences between cancer cells and normal cells, leading to new and more effective treatments for patients with cancer.
- FDA Approves Pembrolizumab for Patients with Non-Small Cell Lung Cancer
The FDA has approved the drug pembrolizumab to treat patients with advanced non-small cell lung cancer (NSCLC) whose tumors express a protein called PD-L1.
- Low Income Is a Barrier to Clinical Trial Enrollment, Study Suggests
A new study has found that patients with annual household incomes below $50,000 were less likely to participate in a cancer clinical trial than those with higher incomes.
- Antioxidants Accelerate the Growth and Invasiveness of Tumors in Mice
Metastatic tumor cells are particularly sensitive to oxidative stress, and antioxidant supplementation increases their ability to grow and metastasize.
- FDA Approves Nivolumab for Some Melanomas and Lung Cancers
The FDA has approved nivolumab in combination with ipilimumab for advanced melanoma and nivolumab alone for advanced nonsquamous lung cancer.